Arsenic disruption of DNA damage responses—potential role in carcinogenesis and chemotherapy

Biomolecules

Volumn 5, Issue 4, 2015, Pages 2184-2193

  Muenyi, Clarisse S ^a   Ljungman, Mats ^b   States, J Christopher ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Arsenic; DNA damage response; DNA repair; MSH2; Ubiquitination; XPC

Indexed keywords

ARSENIC; ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 1; XRCC1 PROTEIN;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL CYCLE ARREST; DNA DAMAGE; DNA REPAIR; ENVIRONMENTAL EXPOSURE; EPIGENETICS; EXCISION REPAIR; GENE EXPRESSION; HUMAN; MISMATCH REPAIR; MUTAGENESIS; NEOPLASM; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; CELL CYCLE; DRUG EFFECTS;

ANIMALS; ARSENIC; CARCINOGENESIS; CELL CYCLE; DNA DAMAGE; DNA REPAIR; HUMANS; UBIQUITINATION;

EID: 85012050570     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5042184     Document Type: Review

References (64)

1. Cui, X.; Kobayashi, Y.; Akashi, M.; Okayasu, R. Metabolism and the paradoxical effects of arsenic: Carcinogenesis and anticancer. Curr. Med. Chem. 2008, 15, 2293–2304.
2. Desoize, B. Metals and metal compounds in cancer treatment. Anticancer Res. 2004, 24, 1529–1544.
3. Gibb, H.; Haver, C.; Gaylor, D.; Ramasamy, S.; Lee, J.S.; Lobdell, D.; Wade, T.; Chen, C.; White, P.; Sams, R. Utility of recent studies to assess the national research council 2001 estimates of cancer risk from ingested arsenic. Environ. Health Perspect. 2011, 119, 284–290.
4. Mondal, D.; Banerjee, M.; Kundu, M.; Banerjee, N.; Bhattacharya, U.; Giri, A.K.; Ganguli, B.; Roy, S.S.; Polya, D.A. Comparison of drinking water, raw rice and cooking of rice as arsenic exposure routes in three contrasting areas of West Bengal, India. Environ. Geochem. Health 2010, 32, 463–477.
5. Saint-Jacques, N.; Parker, L.; Brown, P.; Dummer, T.J. Arsenic in drinking water and urinary tract cancers: A systematic review of 30 years of epidemiological evidence. Environ. Health 2014, doi:10.1186/1476-069X-13-44.
6. Steinmaus, C.; Ferreccio, C.; Yuan, Y.; Acevedo, J.; Gonzalez, F.; Perez, L.; Cortes, S.; Balmes, J.R.; Liaw, J.; Smith, A.H. Elevated lung cancer in younger adults and low concentrations of arsenic in water. Am. J. Epidemiol. 2014, 180, 1082–1087.
7. Wang, W.; Cheng, S.; Zhang, D. Association of inorganic arsenic exposure with liver cancer mortality: A meta-analysis. Environ. Res. 2014, 135, 120–125.
8. Tokar, E.J.; Qu, W.; Liu, J.; Liu, W.; Webber, M.M.; Phang, J.M.; Waalkes, M.P. Arsenic-specific stem cell selection during malignant transformation. J. Nat. Cancer Inst. 2010, 102, 638–649.
9. Salazar, A.M.; Miller, H.L.; McNeely, S.C.; Sordo, M.; Ostrosky-Wegman, P.; States, J.C. Suppression of p53 and p21CIP1/WAF1 reduces arsenite-induced aneuploidy. Chem. Res. Toxicol. 2010, 23, 357–364.
10. Vega, L.; Gonsebatt, M.E.; Ostrosky-Wegman, P. Aneugenic effect of sodium arsenite on human lymphocytes in vitro: An individual susceptibility effect detected. Mutat. Res. 1995, 334, 365–373.
11. Waalkes, M.P.; Qu, W.; Tokar, E.J.; Kissling, G.E.; Dixon, D. Lung tumors in mice induced by “whole-life” inorganic arsenic exposure at human-relevant doses. Arch. Toxicol. 2014, 88, 1619–1629.
12. Burns, F.J.; Uddin, A.N.; Wu, F.; Nadas, A.; Rossman, T.G. Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: A dose-response study. Environ. Health Perspect. 2004, 112, 599–603.
13. Rossman, T.G.; Uddin, A.N.; Burns, F.J. Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol. Appl. Pharmacol. 2004, 198, 394–404.
14. Rossman, T.G.; Uddin, A.N.; Burns, F.J.; Bosland, M.C. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. Toxicol. Appl. Pharmacol. 2001, 176, 64–71.
15. Rossman, T.G.; Uddin, A.N.; Burns, F.J.; Bosland, M.C. Arsenite cocarcinogenesis: An animal model derived from genetic toxicology studies. Environ. Health Perspect. 2002, 110, S749–S752.
16. Schwarz, M.; Munzel, P.A.; Braeuning, A. Non-melanoma skin cancer in mouse and man. Arch. Toxicol. 2013, 87, 783–798.
17. Waalkes, M.P.; Liu, J.; Germolec, D.R.; Trempus, C.S.; Cannon, R.E.; Tokar, E.J.; Tennant, R.W.; Ward, J.M.; Diwan, B.A. Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics. Cancer Res. 2008, 68, 8278–8285.
18. Andrew, A.S.; Karagas, M.R.; Hamilton, J.W. Decreased DNA repair gene expression among individuals exposed to arsenic in united states drinking water. Int. J. Cancer 2003, 104, 263–268.
19. Andrew, A.S.; Burgess, J.L.; Meza, M.M.; Demidenko, E.; Waugh, M.G.; Hamilton, J.W.; Karagas, M.R. Arsenic exposure is associated with decreased DNA repair in vitro and in individuals exposed to drinking water arsenic. Environ. Health Perspect. 2006, 114, 1193–1198.
20. Kelsey, K.T.; Hirao, T.; Hirao, S.; Devi-Ashok, T.; Nelson, H.H.; Andrew, A.; Colt, J.; Baris, D.; Morris, J.S.; Schned, A et al. Tp53 alterations and patterns of carcinogen exposure in a US Population-based study of bladder cancer. Int. J. Cancer 2005, 117, 370–375.
21. Shibata, A.; Ohneseit, P.F.; Tsai, Y.C.; Spruck, C.H., 3rd; Nichols, P.W.; Chiang, H.S.; Lai, M.K.; Jones, P.A. Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in taiwan. Carcinogenesis 1994, 15, 1085–1087.
22. Brash, D.E. Roles of the transcription factor p53 in keratinocyte carcinomas. Br. J. Dermatol. 2006, 154, S8–S10.
23. Castren, K.; Ranki, A.; Welsh, J.A.; Vahakangas, K.H. Infrequent p53 mutations in arsenic-related skin lesions. Oncol. Res. 1998, 10, 475–482.
24. Hsieh, L.L.; Chen, H.J.; Hsieh, J.T.; Jee, S.H.; Chen, G.S.; Chen, C.J. Arsenic-related bowen’s disease and paraquat-related skin cancerous lesions show no detectable ras and p53 gene alterations. Cancer Lett. 1994, 86, 59–65.
25. Hsu, C.H.; Yang, S.A.; Wang, J.Y.; Yu, H.S.; Lin, S.R. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br. J. Cancer 1999, 80, 1080–1086.
26. Komissarova, E.V.; Rossman, T.G. Arsenite induced poly(ADP-ribosyl)ation of tumor suppressor p53 in human skin keratinocytes as a possible mechanism for carcinogenesis associated with arsenic exposure. Toxicol. Appl. Pharmacol. 2010, 243, 399–404.
27. Ding, W.; Liu, W.; Cooper, K.L.; Qin, X.J.; de Souza Bergo, P.L.; Hudson, L.G.; Liu, K.J. Inhibition of poly (ADP-ribose) polymerase-1 by arsenite interferes with repair of oxidative DNA damage. J. Biol. Chem. 2009, 284, 6809–6817.
28. Sun, X.; Zhou, X.; Du, L.; Liu, W.; Liu, Y.; Hudson, L.G.; Liu, K.J. Arsenite binding-induced zinc loss from parp-1 is equivalent to zinc deficiency in reducing parp-1 activity, leading to inhibition of DNA repair. Toxicol. Appl. Pharmacol. 2014, 274, 313–318.
29. McNeely, S.C.; Belshoff, A.C.; Taylor, B.F.; Fan, T.W.; McCabe, M.J., Jr.; Pinhas, A.R.; States, J.C. Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest. Toxicol. Appl. Pharmacol. 2008, 229, 252–261.
30. McNeely, S.C.; Taylor, B.F.; States, J.C. Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent. Toxicol. Appl. Pharmacol. 2008, 231, 61–67.
31. Taylor, B.F.; McNeely, S.C.; Miller, H.L.; Lehmann, G.M.; McCabe, M.J., Jr.; States, J.C. p53 Suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1. J. Pharmacol. Exp. Ther. 2006, 318, 142–151.
32. Bau, D.T.; Wang, T.S.; Chung, C.H.; Wang, A.S.; Wang, A.S.; Jan, K.Y. Oxidative DNA adducts and DNA-protein cross-links are the major DNA lesions induced by arsenite. Environ. Health Perspect. 2002, 110, S753–S756.
33. Salnikow, K.; Zhitkovich, A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: Nickel, arsenic, and chromium. Chem. Res. Toxicol. 2008, 21, 28–44.
34. Shi, H.; Hudson, L.G.; Ding, W.; Wang, S.; Cooper, K.L.; Liu, S.; Chen, Y.; Shi, X.; Liu, K.J. Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals. Chem. Res. Toxicol. 2004, 17, 871–878.
35. Shi, H.; Hudson, L.G.; Liu, K.J. Oxidative stress and apoptosis in metal ion-induced carcinogenesis. Free. Radic. Biol. Med. 2004, 37, 582–593.
36. Shi, H.; Shi, X.; Liu, K.J. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol. Cell. Biochem. 2004, 255, 67–78.
37. Valko, M.; Morris, H.; Cronin, M.T. Metals, toxicity and oxidative stress. Curr. Med. Chem. 2005, 12, 1161–1208.
38. Ebert, F.; Weiss, A.; Bultemeyer, M.; Hamann, I.; Hartwig, A.; Schwerdtle, T. Arsenicals affect base excision repair by several mechanisms. Mutat. Res. 2011, 715, 32–41.
39. Osmond, M.J.; Kunz, B.A.; Snow, E.T. Age and exposure to arsenic alter base excision repair transcript levels in mice. Mutagenesis 2010, 25, 517–522.
40. Hartwig, A.; Pelzer, A.; Asmuss, M.; Burkle, A. Very low concentrations of arsenite suppress poly (ADP-ribosyl)ation in mammalian cells. Int. J. Cancer 2003, 104, 1–6.
41. Schwerdtle, T.; Walter, I.; Hartwig, A. Arsenite and its biomethylated metabolites interfere with the formation and repair of stable BPDE-induced DNA adducts in human cells and impair XPAzf and Fpg. DNA Repair 2003, 2, 1449–1463.
42. Zhang, J.; Wang, B. Arsenic trioxide (As2O3) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol. Oncol. 2006, 103, 199–206.
43. Cohen, M.H.; Hirschfeld, S.; Honig, S.F.; Ibrahim, A.; Johnson, J.R.; O’Leary, J.J.; White, R.M.; Williams, G.A.; Pazdur, R. Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001, 6, 4–11.
44. Nakagawa, Y.; Akao, Y.; Morikawa, H.; Hirata, I.; Katsu, K.; Naoe, T.; Ohishi, N.; Yagi, K. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci. 2002, 70, 2253–2269.
45. Uslu, R.; Sanli, U.A.; Sezgin, C.; Karabulut, B.; Terzioglu, E.; Omay, S.B.; Goker, E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 2000, 6, 4957–4964.
46. Zhang, T.C.; Cao, E.H.; Li, J.F.; Ma, W.; Qin, J.F. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur. J. Cancer 1999, 35, 1258–1263.
47. Maeda, H.; Hori, S.; Nishitoh, H.; Ichijo, H.; Ogawa, O.; Kakehi, Y.; Kakizuka, A. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 2001, 61, 5432–5440.
48. Chun, Y.J.; Park, I.C.; Park, M.J.; Woo, S.H.; Hong, S.I.; Chung, H.Y.; Kim, T.H.; Lee, Y.S.; Rhee, C.H.; Lee, S.J. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS Lett. 2002, 519, 195–200.
49. Wang, W.; Qin, S.K.; Chen, B.A.; Chen, H.Y. Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World J. Gastroenterol. 2001, 7, 702–705.
50. Muenyi, C.S.; States, V.A.; Masters, J.H.; Fan, T.W.; Helm, C.W.; States, J.C. Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). J. Ovarian Res. 2011, 4, doi:10.1186/1757-2215-4-9.
51. Neher, T.M.; Rechkunova, N.I.; Lavrik, O.I.; Turchi, J.J. Photo-cross-linking of XPC-Rad23B to cisplatin-damaged DNA reveals contacts with both strands of the DNA duplex and spans the DNA adduct. Biochemistry 2010, 49, 669–678.
52. Sameer, A.S.; Nissar, S.; Fatima, K. Mismatch repair pathway: Molecules, functions, and role in colorectal carcinogenesis. Eur. J. Cancer Prev. 2014, 23, 246–257.
53. Xiao, X.; Melton, D.W.; Gourley, C. Mismatch repair deficiency in ovarian cancer—Molecular characteristics and clinical implications. Gynecol. Oncol. 2014, 132, 506–512.
54. Martin, L.P.; Hamilton, T.C.; Schilder, R.J. Platinum resistance: The role of DNA repair pathways. Clin. Cancer Res. 2008, 14, 1291–1295.
55. Adimoolam, S.; Ford, J.M. P53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair 2003, 2, 947–954.
56. Ford, J.M. Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. Mutat. Res. 2005, 577, 195–202.
57. Ford, J.M.; Hanawalt, P.C. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc. Natl. Acad. Sci. USA 1995, 92, 8876–8880.
58. Ford, J.M.; Hanawalt, P.C. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem. 1997, 272, 28073–28080.
59. Nollen, M.; Ebert, F.; Moser, J.; Mullenders, L.H.; Hartwig, A.; Schwerdtle, T. Impact of arsenic on nucleotide excision repair: XPC function, protein level, and gene expression. Mol. Nutr. Food Res. 2009, 53, 572–582.
60. Muenyi, C.S.; Pinhas, A.R.; Fan, T.W.; Brock, G.N.; Helm, C.W.; States, J.C. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses. Toxicol. Sci. 2012, 127, 139–149.
61. Muenyi, C.S.; Trivedi, A.P.; Helm, C.W.; States, J.C. Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells. Toxicol. Sci. 2014, 139, 74–82.
62. Paulsen, M.T.; Veloso, A.; Prasad, J.; Bedi, K.; Ljungman, E.A.; Magnuson, B.; Wilson, T.E.; Ljungman, M. Use of Bru-Seq and BruChase-Seq for genome-wide assessment of the synthesis and stability of RNA. Methods 2014, 67, 45–54.
63. Reichard, J.F.; Puga, A. Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. Epigenomics 2010, 2, 87–104.
64. Chervona, Y.; Arita, A.; Costa, M. Carcinogenic metals and the epigenome: Understanding the effect of nickel, arsenic, and chromium. Metallomics 2012, 4, 619–627.